Rosen Law Firm Encourages Hims & Hers Health, Inc. Investors to Inquire About Securities Class Action Investigation
NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Hims & Hers Health, Inc. (NYSE: HIMS) resulting from allegations that Hims & Hers may have issued materially misleading business information to the investing public.
So What: If you purchased Hims & Hers securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.
What to do next: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=40578 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action.
What is this about: On June 23, 2025, before the market opened, Novo Nordisk issued a press release entitled 'Novo Nordisk terminates collaboration with Hims & Hers Health, Inc. due to concerns about their illegal mass compounding and deceptive marketing.' The press release further stated that, in late April, 'the FDA resolved the Wegovy ® shortage based on its conclusion that Novo Nordisk is fully meeting current and projected nationwide demand for this medicine. In support of transitioning patients from knock-off compounded versions to authentic, FDA-approved Wegovy ® through NovoCare ® Pharmacy, Novo Nordisk began collaborating with telehealth companies. Over one month into the collaboration, Hims & Hers Health, Inc. has failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of 'personalization' and are disseminating deceptive marketing that put patient safety at risk.'
On this news, Hims & Hers stock fell over 28% in intraday trading on June 23, 2025.
Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. At the time Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
18 minutes ago
- Newsweek
The Inflation Time Bomb—Trump's Policies Will Hit Your Wallet Soon
Advocates for ideas and draws conclusions based on the interpretation of facts and data. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. With inflation hovering modestly above 2 percent despite President Donald Trump's aggressive tariff increases and immigration enforcement, some might wonder whether warnings about his policies driving up prices were overblown. They weren't. The inflationary pressures are building beneath the surface, masked by timing, supply chain buffers, and massive corporate stockpiling ahead of policy changes. The time bomb is ticking—and consumers should begin bracing for the explosion. Trump's most disruptive policies didn't begin in earnest until months after his January inauguration. While he announced a 10 percent tariff on Chinese goods in late January, the real escalation came in March when rates jumped to 20 percent, then spiked to 145 percent by April before being partially rolled back. The administration's "Liberation Day" universal tariff on April 2 marked the broadest increase since the 1930s. Traders work on the floor of the New York Stock Exchange (NYSE) in New York City on June 18, 2025. Traders work on the floor of the New York Stock Exchange (NYSE) in New York City on June 18, 2025. TIMOTHY A. CLARY/AFP via Getty Images Immigration enforcement followed a similar pattern. Though raids began in January, the most aggressive workplace operations didn't intensify until late May, when Trump aide Stephen Miller pushed for 3,000 arrests per day—triple the early administration pace. Only recently have we seen dramatic workplace disruptions that at one point caused Trump to pull back on raids of farmers, hotels, and other key industries that rely on immigrants for labor. However, that pause proved to only be a brief reprieve, guaranteeing that the inflationary pressures from this aggressive immigration policy will continue to build. What truly delayed the impact of Trump's most inflationary policy was an unprecedented wave of corporate front-loading in late 2024 and early 2025. Companies rushed to import goods before tariffs took effect, creating exactly the buffer that's now insulating consumers from immediate price shocks. These panic purchases were so intense it caused the U.S. economy to contract 0.3 percent in Q1 despite robust domestic demand. By May, container imports fell 9.7 percent as the stockpiling surge ended and higher tariff rates took hold. By stocking up as they did, companies bought themselves time to ride through a few months of high tariffs without it affecting their bottom line. As Trump's trade war drags on, those Q1 stockpiles dwindle as companies forestall replenishing their inventories in the hope that tariff rates will suddenly come down. Freight bookings for April dropped 41 percent month-over-month as businesses adopted this "wait and see" approach. The gap between inventory levels and inventory costs has expanded to the third highest in the index's history. In essence, it is becoming increasingly expensive to store inventory while simultaneously becoming more expensive to replace it. The Federal Reserve's stance reveals perhaps the clearest evidence that policymakers anticipate the inflationary surge ahead. Despite months of consistently lower inflation readings and unprecedented presidential pressure to cut rates, Fed officials have held interest rates steady—a decision that only makes sense if they're bracing for future price pressures. By keeping rates elevated despite political pressure and recent good inflation data, the Fed is acknowledging their belief that current price stability is temporary. They're positioning for the inflationary impact they know is coming rather than reacting to the deceptively calm present. The ingredients for an inflationary surge are now in place: depleted inventory buffers, supply chain disruptions in essential industries, elevated tariffs on a vast array of goods, and increasingly fragile inflation expectations. When companies exhaust their stockpiles and face the choice between absorbing higher costs or passing them to consumers, the answer isn't just predictable, it is a necessary function of the corporate mandate to maximize shareholder value. Food prices are particularly vulnerable. With agricultural raids creating labor shortages during peak growing season and tariffs raising input costs, the sector faces a perfect storm. The lag between policy implementation and consumer impact is ending. Trump's own acknowledgment of economic "harm" from his policies—and his scramble to dial them back—suggests the administration has already seen internal projections of what's coming. The question isn't whether Trump's policies will drive inflation, but when Americans will feel it at the grocery store. The time bomb is real, and the fuse is shortening. Nicholas Creel is an associate professor of business law at Georgia College & State University. The views expressed in this article are the writer's own.
Business Wire
26 minutes ago
- Business Wire
Trially AI Taps Serial Entrepreneur Christian Smith as CRO to Expand AI Clinical Trial Enrollment Across U.S.
KANSAS CITY, Mo.--(BUSINESS WIRE)-- Trially®, a breakthrough AI clinical trial recruitment technology to unlock faster qualified patient enrollment, today announced the appointment of as Chief Revenue Officer. A serial entrepreneur and proven operator, Smith brings a track record of scaling quality service for healthcare organizations and will lead efforts to accelerate trial enrollment for U.S. site networks, healthcare systems, and sponsors with Trially's AI tools. When my mom passed away of breast cancer in 2005, we had no clue there were 28 studies running within driving distance, including studies for Trastuzumab and Bevacizumab which represent some of the top treatments on the market today. Smith joins Trially at a pivotal moment. As clinical research sites face mounting enrollment pressure and shrinking pipelines, Trially has emerged as a category-defining technology. In a landscape where 68% of sites miss enrollment targets and screen failure rates continue to rise, Trially AI is enabling sites to predictably prescreen and qualify patients for trials — with or without an EHR integration — helping teams multiply enrollment for even the most complex protocols in record time. 'In my late teens, I found how difficult it is to navigate medical care when standard treatment paths do not yield results,' said Smith. 'When my mom passed away of breast cancer in 2005, we had no clue there were 28 studies running within driving distance, including studies for Trastuzumab and Bevacizumab which represent some of the top treatments on the market today. It is an honor to join Trially to serve the physician networks and sites by matching patients with novel drug therapies to improve health outcomes and the standard of care.' Prior to Trially, Smith co-founded TrackR, where he helped create the Bluetooth tracking category and grew revenue to over $50 million. During the COVID-19 pandemic, he led direct-to-consumer operations at Dascena, opening 44 testing sites across 26 cities. Most recently, he co-founded Forta, where he pioneered a family centric autism therapy model powered by AI. His expertise in direct-to-patient recruitment, AI-driven care models, and scaling operational quality — are critical to best support Trially partners. 'Christian brings the exact mindset we value at Trially: efficiency, transparency, empathy,' said Trevor Welch, Co-founder and Chief Product Officer of Trially. "He understands what it means to scale with purpose, and he's passionate about empowering research teams to help patients get access to life-saving therapies. His arrival marks a new chapter in our mission to unlock faster qualified patient enrollment across the industry.' About Trially Trially® is shaping the future of clinical trial recruitment with its proprietary AI matching technology that safely unlocks rich clinical data to enroll qualified patients faster. Proven to multiply enrollment rates by 200%, dramatically reduce screen failures and improve site efficiency, Trially's site-based software rapidly integrates with any EHR or CTMS system while maintaining full compliance with HIPAA, SOC 2, FDA 21 CFR Part 11 and ISO 27001 regulations. Designed to meet the needs of physicians, research sites and pharmaceutical sponsors, Trially empowers you to achieve outstanding results in clinical research. For more information visit
Business Wire
26 minutes ago
- Business Wire
Mastercard partners with Fiserv to accelerate mainstream stablecoin adoption
PURCHASE, N.Y.--(BUSINESS WIRE)--Mastercard is deepening its partnership with Fiserv, Inc. (NYSE: FI) to integrate its new FIUSD token across a range of Mastercard products and services, expanding stablecoin adoption and utility for their shared customers around the world. 'Leveraging the power of the Mastercard network, as well as our deep capabilities across digital assets, we are creating a robust ecosystem that bridges traditional financial services with digital assets," said Chiro Aikat, co-president at Mastercard. Share By offering FIUSD across Mastercard's global payments network, people and businesses can use the new, programmable, blockchain-based token across more than 150 million merchants. Mastercard and Fiserv will explore key areas to solve for real-world challenges and opportunities for stablecoin adoption and utility, including: Seamless on and off-ramping: The partnership can enable the efficient on/off-ramping of funds, allowing consumers and businesses to transition smoothly between fiat and FIUSD. Enabling merchants to settle in FIUSD: Mastercard can enable FIUSD as a settlement option for its global acquirers, helping merchants get paid in FIUSD, no matter how they are paid. This not only expands choice but also enhances operational efficiencies and delivers a seamless payment experience. Connectivity to the Mastercard Multi-Token Network (MTN): Fiserv's Digital Asset Platform, powered by Finxact, can leverage Mastercard MTN to bring off-the-shelf support for programmable, on-chain commerce for banks. Powering stablecoin-powered cards: Together, Fiserv and Mastercard will enable the issuance of stablecoin-linked cards for shared customers, allowing consumers and businesses to make FIUSD payments anywhere around the world where Mastercard is accepted. With Mastercard One Credential, consumers can also flexibly choose the payment type of their choice – from debit, credit to stablecoin balances. 'This work with Fiserv is setting the stage for a new era, where stablecoins are as ubiquitous and trusted as fiat currencies, driving choice and innovation for all,' said Chiro Aikat, co-president, Americas at Mastercard. 'Leveraging the power of the Mastercard network, as well as our deep capabilities across digital assets, we are creating a robust ecosystem that bridges traditional financial services with digital assets. Underpinned by our commitment to providing seamless, secure, and programmable transactions, we are excited to bring Fiserv's FIUSD to our customers, consumers and businesses around the world.' 'FIUSD presents Fiserv customers with access to a new, more efficient, and interoperable digital asset service for their banking and payment flows. To date, stablecoins have largely been a store of value. Our work with Mastercard is promoting greater reach and utility of stablecoins by helping our financial institutions and merchants enable greater payments choice to their customers,' said Takis Georgakopoulos, Chief Operating Officer, Fiserv. About Mastercard Mastercard powers economies and empowers people in 200+ countries and territories worldwide. Together with our customers, we're building a resilient economy where everyone can prosper. We support a wide range of digital payments choices, making transactions secure, simple, smart and accessible. Our technology and innovation, partnerships and networks combine to deliver a unique set of products and services that help people, businesses and governments realize their greatest potential. About Fiserv, Inc. Fiserv, Inc. (NYSE: FI), a Fortune 500 company, moves more than money. As a global leader in payments and financial technology, the company helps clients achieve best-in-class results through a commitment to innovation and excellence in areas including account processing and digital banking solutions; card issuer processing and network services; payments; e-commerce; merchant acquiring and processing; and Clover ®, the world's smartest point-of-sale system and business management platform. Fiserv is a member of the S&P 500 ® Index and one of Fortune ® World's Most Admired Companies™.
